TGTX TG THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TG THERAPEUTICS INC reported revenue of $240M (up 70.3% from a year earlier), net income of $7.78M and diluted EPS of $0.05; over the last four quarters revenue was $800M and net income $442M; for the fiscal year ended December 2025 revenue was $616M, up 87.3% on the year before.
TGTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $616M, gross profit n/a, operating income $123M, net income $447M (margin 72.6%), EPS $2.77
- Fiscal year ended Dec 2024: revenue $329M, gross profit n/a, operating income $41.9M, net income $23.4M (margin 7.1%), EPS $0.15
- Fiscal year ended Dec 2023: revenue $234M, gross profit n/a, operating income $20.6M, net income $12.7M (margin 5.4%), EPS $0.09
- Fiscal year ended Dec 2022: revenue $2.79M, gross profit n/a, operating income −$218M, net income −$198M (margin -7120.3%), EPS −$1.65
- Fiscal year ended Dec 2021: revenue $6.69M, gross profit n/a, operating income −$345M, net income −$348M (margin -5204.1%), EPS −$2.63
TGTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $240M (up 70.3% year over year), net income $7.78M, EPS $0.05
- Quarter ended Mar 31, 2026: revenue $205M (up 69.6% year over year), net income $19.8M, EPS $0.12
- Quarter ended Dec 31, 2025 (from the annual report): revenue $193M (up 78.0% year over year), net income $23.1M, EPS $0.14
- Quarter ended Sep 30, 2025: revenue $162M (up 92.8% year over year), net income $391M, EPS $2.43
- Quarter ended Jun 30, 2025: revenue $141M (up 92.1% year over year), net income $28.2M, EPS $0.17
- Quarter ended Mar 31, 2025: revenue $121M (up 90.4% year over year), net income $5.06M, EPS $0.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue $108M (up 146.0% year over year), net income $23.3M, EPS $0.16
- Quarter ended Sep 30, 2024: revenue $83.9M (down 49.4% year over year), net income $3.88M, EPS $0.02
- Quarter ended Jun 30, 2024: revenue $73.5M (up 357.0% year over year), net income $6.88M, EPS $0.04
- Quarter ended Mar 31, 2024: revenue $63.5M (up 713.5% year over year), net income −$10.7M, EPS −$0.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue $44.0M (up 54184.0% year over year), net income −$14.4M, EPS −$0.02
- Quarter ended Sep 30, 2023: revenue $166M (up 176298.9% year over year), net income $114M, EPS $0.73
- Quarter ended Jun 30, 2023: revenue $16.1M (up 2606.1% year over year), net income −$47.6M, EPS −$0.34
- Quarter ended Mar 31, 2023: revenue $7.80M (up 287.1% year over year), net income −$39.2M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue $81.0K (down 96.5% year over year), net income −$53.0M, EPS −$0.58
- Quarter ended Sep 30, 2022: revenue $94.0K (down 95.4% year over year), net income −$35.8M, EPS −$0.26
- Quarter ended Jun 30, 2022: revenue $594K (down 61.6% year over year), net income −$40.5M, EPS −$0.30
- Quarter ended Mar 31, 2022: revenue $2.02M (up 154.2% year over year), net income −$69.0M, EPS −$0.51
- Quarter ended Dec 31, 2021 (from the annual report): revenue $2.32M, net income −$93.3M, EPS −$0.70
- Quarter ended Sep 30, 2021: revenue $2.03M, net income −$85.6M, EPS −$0.65
TGTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$24.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$40.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$31.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$176M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$296M, share buybacks n/a
TGTX balance sheet
- Jun 30, 2026: cash $483M, total assets $1.64B, total liabilities $1.04B, shareholders' equity $604M, long-term debt $745M
- Mar 31, 2026: cash $442M, total assets $1.53B, total liabilities $946M, shareholders' equity $583M, long-term debt $745M
- Dec 31, 2025: cash $79.1M, total assets $1.06B, total liabilities $415M, shareholders' equity $648M, long-term debt $246M
- Sep 30, 2025: cash $74.1M, total assets $1.03B, total liabilities $418M, shareholders' equity $607M, long-term debt $245M
- Jun 30, 2025: cash $129M, total assets $703M, total liabilities $426M, shareholders' equity $276M, long-term debt $245M
- Mar 31, 2025: cash $132M, total assets $657M, total liabilities $419M, shareholders' equity $237M, long-term debt $245M
- Dec 31, 2024: cash $180M, total assets $578M, total liabilities $355M, shareholders' equity $222M, long-term debt $244M
- Sep 30, 2024: cash $196M, total assets $586M, total liabilities $394M, shareholders' equity $192M, long-term debt $244M
What is TGTX's revenue?
TG THERAPEUTICS INC reported $800M of revenue over its last four quarters, through June 30, 2026.
Is TGTX profitable?
Yes. TG THERAPEUTICS INC earned $442M over the last four quarters.
What is TGTX's EPS?
Diluted earnings per share over the last four quarters were $2.74; $0.05 in the latest quarter.